secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001558370-23-011550
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix adjourns annual meeting to solicit votes for authorized share increase to 185M
--------------------------------------------------------------------------------

- Meeting approved election of 7 directors; votes ranged from 30.1M to 30.7M for, 2.2M to 2.7M withheld.
- Stock plan amendment approved: shares available increased from 8.475M to 12.475M (25.8M for, 6.9M against).
- Advisory vote on say-on-pay frequency favored one year (30.3M votes); board adopts annual frequency.
- Meeting adjourned to July 13, 2023 to solicit more votes for charter amendment increasing authorized shares from 144M to 185M.
- Ratification of PwC as auditor approved with 36.8M for, 2.7M against; broker non-votes existed on other items.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/0001558370-23-011550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023011550/plx-20230628x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-011550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer